Nordea Investment Management AB Trims Position in Elevance Health, Inc. $ELV

Nordea Investment Management AB cut its stake in shares of Elevance Health, Inc. (NYSE:ELV) by 16.8% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 340,267 shares of the company’s stock after selling 68,527 shares during the period. Nordea Investment Management AB’s holdings in Elevance Health were worth $119,420,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Physician Wealth Advisors Inc. grew its stake in Elevance Health by 331.6% during the third quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock valued at $26,000 after acquiring an additional 63 shares in the last quarter. Activest Wealth Management lifted its stake in Elevance Health by 66.7% in the 3rd quarter. Activest Wealth Management now owns 85 shares of the company’s stock worth $27,000 after purchasing an additional 34 shares in the last quarter. Rossby Financial LCC lifted its stake in Elevance Health by 110.0% in the 3rd quarter. Rossby Financial LCC now owns 84 shares of the company’s stock worth $28,000 after purchasing an additional 44 shares in the last quarter. Vermillion & White Wealth Management Group LLC boosted its holdings in Elevance Health by 94.9% in the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 76 shares of the company’s stock valued at $30,000 after purchasing an additional 37 shares during the period. Finally, Motco grew its position in shares of Elevance Health by 334.8% during the 3rd quarter. Motco now owns 100 shares of the company’s stock valued at $32,000 after purchasing an additional 77 shares in the last quarter. 89.24% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Mizuho decreased their price target on shares of Elevance Health from $413.00 to $350.00 and set an “outperform” rating on the stock in a report on Wednesday, March 11th. Robert W. Baird boosted their target price on Elevance Health from $297.00 to $340.00 and gave the stock a “neutral” rating in a research report on Thursday, December 11th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $332.00 target price on shares of Elevance Health in a research note on Thursday, January 29th. Jefferies Financial Group lowered their price target on Elevance Health from $401.00 to $395.00 and set a “buy” rating on the stock in a report on Friday, January 30th. Finally, Weiss Ratings downgraded Elevance Health from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, February 2nd. Twelve research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Elevance Health has a consensus rating of “Moderate Buy” and a consensus price target of $387.40.

Elevance Health Stock Performance

NYSE ELV opened at $291.90 on Monday. Elevance Health, Inc. has a 52-week low of $273.71 and a 52-week high of $458.75. The company has a fifty day moving average of $330.59 and a 200-day moving average of $333.57. The company has a market capitalization of $64.43 billion, a P/E ratio of 11.62, a P/E/G ratio of 1.60 and a beta of 0.51. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.54 and a current ratio of 1.54.

Elevance Health (NYSE:ELV) last released its earnings results on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, beating analysts’ consensus estimates of $3.10 by $0.23. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The business had revenue of $49.31 billion for the quarter, compared to analysts’ expectations of $49.52 billion. During the same quarter in the prior year, the firm earned $3.84 earnings per share. The firm’s revenue was up 9.6% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 25.500- EPS. As a group, equities research analysts predict that Elevance Health, Inc. will post 33.96 EPS for the current fiscal year.

Elevance Health Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Stockholders of record on Tuesday, March 10th will be given a dividend of $1.72 per share. This is a boost from Elevance Health’s previous quarterly dividend of $1.71. The ex-dividend date is Tuesday, March 10th. This represents a $6.88 annualized dividend and a dividend yield of 2.4%. Elevance Health’s dividend payout ratio is currently 27.39%.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.